Knockdown of peroxiredoxin 5 inhibits the growth of osteoarthritic chondrocytes via upregulating Wnt/β-catenin signaling

Peroxiredoxin 5 is a member of the peroxiredoxin family, which has been shown to act as an antioxidant whose main function is to reduce reactive oxygen species in cells. Peroxiredoxin 5 has been found to be abnormally elevated in human osteoarthritic chondrocytes. However, the detailed mechanism by which peroxiredoxin 5 modulates human osteoarthritic chondrocytes’ survival has not been elucidated. In the current study, we demonstrated that peroxiredoxin 5 knockdown activated osteoarthritic chondrocytes apoptosis, and decreased scavenging of endogenous reactive oxygen species. Furthermore, silencing of peroxiredoxin 5 resulted in an altered expression of proteins associated with Wnt signaling. Collectively, these results demonstrated that the regulatory effects of peroxiredoxin 5 can be partially attributed to Wnt/β-catenin signaling.     

Soy protein may alleviate osteoarthritis symptoms

Alternative and complementary therapeutic approaches, such as the use of a wide array of herbal, nutritional, and physical manipulations, are becoming popular for relieving symptoms of osteoarthritis (OA). The present study evaluated the efficacy of soy protein (SP) supplementation in relieving the pain and discomfort associated with OA. One hundred and thirty-five free-living individuals (64 men and 71 women) with diagnosed OA or with self-reported chronic knee joint pain not attributed to injury or rheumatoid arthritis were recruited for this double-blind, placebo-controlled, parallel design study. Study participants were assigned randomly to consume 40 g of either supplemental SP or milk-based protein (MP) daily for 3 months. Pain, knee range of motion, and overall physical activity were evaluated prior to the start of treatment and monthly thereafter. Serum levels of glycoprotein 39 (YKL-40), a marker of cartilage degradation, and insulin-like growth factor-I (IGF-I), a growth factor associated with cartilage synthesis, were assessed at baseline and at the end of the study. Overall, SP improved OA-associated symptoms such as range of motion and several factors associated with pain and quality of life in comparison to MP. However, these beneficial effects were mainly due to the effect of SP in men rather than women. Biochemical markers of cartilage metabolism further support the efficacy of SP in men as indicated by a significant increase in serum level of IGF-I and a significant decrease in serum level of YKL-40 compared to MP. This study is the first to provide evidence of possible beneficial effects of SP in the management of OA. Examining and verifying the long-term effects of SP on improving symptoms of OA, particularly in men, is warranted.     

A calibrated EMG-informed neuromusculoskeletal model can appropriately account for muscle co-contraction in the estimation of hip joint contact forces in people with hip osteoarthritis

Abnormal hip joint contact forces (HJCF) are considered a primary mechanical contributor to the progression of hip osteoarthritis (OA). Compared to healthy controls, people with hip OA often present with altered muscle activation patterns and greater muscle co-contraction, both of which can influence HJCF. Neuromusculoskeletal (NMS) modelling is non-invasive approach to estimating HJCF, whereby different neural control solutions can be used to estimate muscle forces. Static optimisation, available within the popular NMS modelling software OpenSim, is a commonly used neural control solution, but may not account for an individual’s unique muscle activation patterns and/or co-contraction that are often evident in pathological population. Alternatively, electromyography (EMG)-assisted neural control solutions, available within CEINMS software, have been shown to account for individual activation patterns in healthy people. Nonetheless, their application in people with hip OA, with conceivably greater levels of co-contraction, is yet to be explored. The aim of this study was to compare HJCF estimations using static optimisation (in OpenSim) and EMG-assisted (in CEINMS) neural control solutions during walking in people with hip OA. EMG-assisted neural control solution was more consistent with both EMG and joint moment data than static optimisation, and also predicted significantly higher HJCF peaks (p < 0.001). The EMG-assisted neural control solution also accounted for more muscle co-contraction than static optimisation (p = 0.03), which probably contributed to these higher HJCF peaks. Findings suggest that the EMG-assisted neural control solution may estimate more physiologically plausible HJCF than static optimisation in a population with high levels of co-contraction, such as hip OA.